Post-Market Registry of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Implanted in Peripheral Vessels

Post-Market Registry of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Implanted in Peripheral Vessels

The primary objective of the VBX 17-04 registry is to collect post-market safety and performance data of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft) in peripheral vessels in patients who require interventional treatment

Inclusion Criteria:

• Age ≥ 18 years.
• Signed informed consent form
• Endovascular indication for treatment based on treating physician's best medical judgment.
• Intend for no other stents to be placed in the same peripheral vessel(s) targeted for VBX Stent Graft placement.
• Willingness of the patient to adhere to standard of care follow-up requirements.

Exclusion Criteria:

• Known hypersensitivity to heparin or a previous incident of Heparin-Induced Thrombocytopenia (HIT) type II.
• Participation in concurrent research study or registry which may confound registry results, unless approved by Gore.
• Pregnant or breast-feeding female at time of informed consent signature.
• Life expectancy < 12 months due to comorbidities.
• Use of the VBX Stent Graft is for the treatment of de novo iliac occlusive disease.
• Use of the VBX Stent Graft is for the treatment of aortic coarctations.
• Use of the VBX Stent Graft in the coronary, pulmonary, carotid, vertebral, isolated infrarenal aortic, or vena cava vessels.